文献速递临床试验与 GCP基础与转化研究

个体化医疗中IgGAM与标准治疗对比治疗感染源控制后腹膜炎(PEPPER试验):随机对照试验研究方案

Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-03-04

PEPPER试验为随机对照试验研究方案,计划纳入200例脓毒症或脓毒性休克患者接受标准治疗,其中133例按1:2随机额外接受IgGAM输注5天,随访约90天,评估多器官衰竭评分、生活质量量表、生命体征、生物标志物及生存,旨在描述性检验高炎症(IL-6)和免疫低下(低HLA-DR、低免疫球蛋白)患者接受IgGAM后结局更优的假设。

要点

  • 200例脓毒症或脓毒性休克患者接受标准治疗,其中133例按1:2随机额外接受IgGAM输注5天。
  • 所有患者随访约90天,评估多器官衰竭评分、EQ QLQ 5D生活质量量表、生命体征、生物标志物及生存。
  • 研究旨在描述性检验高IL-6且低HLA-DR、低免疫球蛋白患者接受IgGAM后结局更优的假设。

核心结论

  • 研究旨在提供IgGAM治疗有效性和安全性的进一步信息,并探索其与所研究生物标志物的关联,从而可能为个体化医疗开辟道路。

研究设计与样本

  • 随机对照试验研究方案,计划纳入200例脓毒症或脓毒性休克患者接受标准治疗。
  • 其中133例患者按1:2随机额外接受IgGAM输注5天。
  • 所有患者随访约90天,评估多器官衰竭评分、EQ QLQ 5D生活质量量表、生命体征、生物标志物及生存。
  • 试验注册号:EudraCT 2016-001788-34;ClinicalTrials.gov NCT03334006,注册日期2017年11月17日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peritonitis is responsible for thousands of deaths annually in Germany alone. Even source control (SC) and antibiotic treatment often fail to prevent severe sepsis or septic shock, and this situation has hardly improved in the past two decades. Most experimental immunomodulatory therapeutics for sepsis have been aimed at blocking or dampening a specific pro-inflammatory immunological mediator. However, the patient collective is large and heterogeneous. There are therefore grounds for investigating the possibility of developing personalized therapies by classifying patients into groups according to biomarkers. This study aims to combine an assessment of the efficacy of treatment with a preparation of human immunoglobulins G, A, and M (IgGAM) with individual status of various biomarkers (immunoglobulin level, procalcitonin, interleukin 6, antigen D-related human leucocyte antigen (HLA-DR), transcription factor NF-κB1, adrenomedullin, and pathogen spectrum). METHODS/DESIGN: A total of 200 patients with sepsis or septic shock will receive standard-of-care treatment (SoC). Of these, 133 patients (selected by 1:2 randomization) will in addition receive infusions of IgGAM for 5 days. All patients will be followed for approximately 90 days and assessed by the multiple-organ failure (MOF) score, by the EQ QLQ 5D quality-of-life scale, and by measurement of vital signs, biomarkers (as above), and survival. DISCUSSION: This study is intended to provide further information on the efficacy and safety of treatment with IgGAM and to offer the possibility of correlating these with the biomarkers to be studied. Specifically, it will test (at a descriptive level) the hypothesis that patients receiving IgGAM who have higher inflammation status (IL-6) and poorer immune status (low HLA-DR, low immunoglobulin levels) have a better outcome than patients who do not receive IgGAM. It is expected to provide information that will help to close the knowledge gap concerning the association between the effect of IgGAM and the presence of various biomarkers, thus possibly opening the way to a personalized medicine. TRIAL REGISTRATION: EudraCT, 2016-001788-34; ClinicalTrials.gov, NCT03334006 . Registered on 17 Nov 2017. Trial sponsor: RWTH Aachen University, represented by the Center for Translational & Clinical Research Aachen (contact Dr. S. Isfort).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kalvelage C, Zacharowski K, Bauhofer A, et al. Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial. Trials. 2019. PMID: 30832742. doi:10.1186/s13063-019-3244-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。